OC
TRVI icon

Oppenheimer & Co’s Trevi Therapeutics TRVI Stock Holding History

Oppenheimer & Co’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86M Sell
99,771
-256
-0.3% -$3.72K 0.02% 665
2026
Q1 		$1.19M Sell
100,027
-671
-0.7% -$7.51K 0.01% 792
2025
Q4 		$1.26M Buy
100,698
+2,030
+2% +$23.5K 0.02% 709
2025
Q3 		$903K Sell
98,668
-1,157
-1% -$8.68K 0.01% 945
2025
Q2 		$546K Sell
99,825
-612
-0.6% -$3.81K 0.01% 1108
2025
Q1 		$632K Buy
100,437
+19,034
+23% +$90.8K 0.01% 997
2024
Q4 		$335K Sell
81,403
-544
-0.7% -$1.74K 0.01% 1212
2024
Q3 		$274K Buy
81,947
+21,128
+35% +$62.8K ﹤0.01% 1285
2024
Q2 		$181K Buy
60,819
+404
+0.7% +$1.12K ﹤0.01% 1349
2024
Q1 		$208K Buy
+60,415
New +$135K ﹤0.01% 1328

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Oppenheimer & Co's TRVI Position: Q2 2026 in Review

Oppenheimer & Co reduced its Trevi Therapeutics (TRVI) stake by 0.26% in Q2 2026, selling an estimated $3.72K and leaving 99,771 shares worth $1.86M. The position accounts for 0.02% of the portfolio, ranked #665.

Oppenheimer & Co first reported a position in TRVI in Q1 2024 and has held it in 10 quarters since. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Oppenheimer & Co held 99,771 shares of Trevi Therapeutics worth $1.86M as of Q2 2026.
  • Oppenheimer & Co sold 256 Trevi Therapeutics shares in Q2 2026, an estimated $3.72K.
  • Trevi Therapeutics made up 0.02% of Oppenheimer & Co's portfolio in Q2 2026, its #665 holding.
  • Oppenheimer & Co first reported a position in Trevi Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.